An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein by McCready, Jessica et al.
Digital Commons @ Assumption University 
Biological and Physical Sciences Department 
Faculty Works Biological and Physical Sciences Department 
2014 
An Impermeant Ganetespib Analog Inhibits Extracellular 
Hsp90-Mediated Cancer Cell Migration that Involves Lysyl 
Oxidase 2-like Protein 
Jessica McCready 
Assumption College, j.mccready@assumption.edu 
Daniel S. Wong 
Tufts University 
Joseph A. Burlison 
Synta Pharmaceuticals 
Weiwen Ying 
Synta Pharmaceuticals 
Daniel G. Jay 
Tufts University 
Follow this and additional works at: https://digitalcommons.assumption.edu/sciences-faculty 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Recommended Citation 
McCready, J.; Wong, D. S. ; Burlison, J. A. ; Ying, W.; and Jay, D. G. (2014). An Impermeant Ganetespib 
Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like 
Protein. Cancers 6(2): 1031-1046. https://doi.org/10.3390/cancers6021031 
This Article is brought to you for free and open access by the Biological and Physical Sciences Department at 
Digital Commons @ Assumption University. It has been accepted for inclusion in Biological and Physical Sciences 
Department Faculty Works by an authorized administrator of Digital Commons @ Assumption University. For more 
information, please contact digitalcommons@assumption.edu. 
Cancers 2014, 6, 1031-1046; doi:10.3390/cancers6021031 
 
cancers 
ISSN 2072-6694 
www.mdpi.com/journal/cancers 
Article 
An Impermeant Ganetespib Analog Inhibits Extracellular 
Hsp90-Mediated Cancer Cell Migration that Involves Lysyl 
Oxidase 2-like Protein 
Jessica McCready 
1,†
, Daniel S. Wong 
2,3†
, Joseph A. Burlison 
4
, Weiwen Ying 
4
 and  
Daniel G. Jay 
2,3
* 
1
 Department of Natural Sciences, Assumption College, Worcester, MA 01609, USA;  
E-Mail: j.mccready@assumption.edu 
2 
Department of Developmental Molecular and Chemical Biology, Tufts University School of 
Medicine, Boston, MA 02111, USA; E-Mail: daniel_s.wong@tufts.edu 
3
 Cell and Molecular Physiology Program, Sackler School of Graduate Biomedical Sciences,  
Tufts University, Boston, MA 02111, USA 
4
 Synta Pharmaceuticals, Lexington, MA 02421, USA; E-Mails: joeburlison@gmail.com (J.A.B.); 
wying@syntapharma.com (W.Y.) 
†
 These authors contributed equally to the work. 
* Author to whom correspondence should be addressed; E-Mail: daniel.jay@tufts.edu. 
Received: 12 December 2013; in revised form: 12 March 2014 / Accepted: 8 April 2014 /  
Published: 30 April 2014 
 
Abstract: Extracellular Hsp90 (eHsp90) activates a number of client proteins outside of 
cancer cells required for migration and invasion. Therefore, eHsp90 may serve as a novel 
target for anti-metastatic drugs as its inhibition using impermeant Hsp90 inhibitors would 
not affect the numerous vital intracellular Hsp90 functions in normal cells. While some 
eHsp90 clients are known, it is important to establish other proteins that act outside the cell 
to validate eHsp90 as a drug target to limit cancer spread. Using mass spectrometry we 
identified two precursor proteins Galectin 3 binding protein (G3BP) and Lysyl oxidase  
2-like protein (LOXL2) that associate with eHsp90 in MDA-MB231 breast cancer cell 
conditioned media and confirmed that LOXL2 binds to eHsp90 in immunoprecipitates. We 
introduce a novel impermeant Hsp90 inhibitor STA-12-7191 derived from ganetespib and 
show that it is markedly less toxic to cells and can inhibit cancer cell migration in a dose 
dependent manner. We used STA-12-7191 to test if LOXL2 and G3BP are potential 
eHsp90 clients. We showed that while LOXL2 can increase wound healing and 
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compensate for STA-12-7191-mediated inhibition of wound closure, addition of G3BP had 
no affect on this assay. These findings support of role for LOXL2 in eHsp90 stimulated 
cancer cell migration and provide preliminary evidence for the use of STA-12-7191 to 
inhibit eHsp90 to limit cancer invasion. 
Keywords: extracellular Hsp90; ganetespib; lysyl oxidase 2-like protein; cancer cell migration 
 
1. Introduction 
The vast majority of cancer related deaths result not from the primary tumor, but from metastasis. 
There are currently no anti-metastasis drugs and developing such drugs would address an important 
unmet need in cancer treatment. Metastasis is a complex multi-step process initiated by invasion of 
tumor cells into the extra-tumor environment, extravasation into the circulatory or lymphatic system, 
survival of these cells while circulating and homing and invasion into a secondary site and finally 
survival and proliferation in the new environment [1]. While interfering with any of these steps would 
be useful, we reasoned that invasion as a first step in metastasis would have promise in containing tumors. 
To identify novel proteins that act in invasiveness, we applied a functional proteomic screen using 
Fluorophore-Assisted Light Inactivation targeted with antibody libraries selected against proteins 
expressed on the surface of HT-1080 fibrosarcoma cells [2] This screen revealed three proteins newly 
implicated in invasion [3,4] and the most intriguing is extracellular Hsp90 (eHsp90). Hsp90 is a highly 
abundant intracellular protein that serves as a molecular chaperone for hundreds of client protein inside 
of cells [5,6] but demonstration of its role outside of cells had been limited [7]. Our study demonstrated 
that the alpha (but not beta) isoform of Hsp90 is found on the surface of HT1080 fibrosarcoma cells 
and that its inhibition reduces cell invasiveness and migration [2]. Moreover, eHsp90 activated the 
matrix metalloproteinase 2 (MMP2) by processing pro-MMP2 and the reduced invasion by specific 
inhibition of eHsp90 could be rescued by addition of active MMP2 to the cells. 
Since our initial discovery of eHsp90 in cancer invasion [2], there have been numerous publications 
implicating eHsp90 in cancer and other diseases and have identified new extracellular clients and 
cellular processes impacted by eHsp90 [8] especially in cancers such as breast [9,10] colorectal [11] 
GBM [12], and prostate [13]. In addition to our work on MMP2, others have shown the following to 
be eHsp90 clients: MMP9 [14]; human EGF receptor 2 (HER2 [9]; and LDL Receptor-like protein 
(LRP-1 [13,15]; which are all involved in cancer invasiveness and other disease-relevant processes [8]. 
For example, to identify binders of eHsp90 we used mass spectrometry analysis of Hsp90 alpha 
immunoprecipitation from MB-231 breast cancer cell conditioned media to identify a pro-form of 
tissue plasminogen activator (TPA) and then showed that active TPA could rescue eHsp90 inhibition-
mediated loss of cell migration [10]. Together, these studies have shown important roles for eHsp90 in 
cell migration and ECM remodeling [10,14], and epithelial to mesenchymal transition [13]. Additionally 
inhibition of eHsp90 in mouse models for metastasis have shown benefit in survival and reduced 
metastasis suggesting the clinical potential of inhibiting the extracellular roles of Hsp90 without 
affecting its intracellular functions. 
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While these studies have expanded the repertoire of eHsp90 clients, our understanding of its novel 
cancer relevant processes remains incomplete. Identifying and validating new extracellular clients for 
eHsp90 and determining their roles in cancer progression and metastasis will inform optimal design of 
eHsp90 drugs for reducing metastasis and establishing a serum biomarker for drug efficacy. In this 
paper, we report additional mass spectrometry analysis of Hsp90 binders in conditioned media and we 
test if eHsp90’s role in enhancing cell migration (a critical component of invasion) has any 
contribution from these binders using a novel impermeant Hsp90 inhibitor derived from ganetespib,  
a promising drug currently in clinical trials [16,17]. 
2. Results and Discussion 
2.1. Mass Spectrometry Analysis of Hsp90 Binders from Conditioned Media 
In addition to TPA [10], several other pro-proteins were identified as eHsp90 binders from  
MDA-MB231 conditioned media. Mass spectrometry analysis indicates that the protein with the 
highest number of peptides following trypsin digestion (Table 1) was Galectin-3 binding protein 
(G3BP), followed by the precursor form of Lysyl Oxidase-like 2 protein (LOXL2) (Table 1). G3BP 
and LOXL2 are both interesting candidates for eHsp90 activation because of their roles in cancer. 
G3BP (also called Mac2 Binding Protein) was identified as a secreted glycoprotein in macrophages [18] 
and found in human breast carcinoma and in breast milk [19]. It has been extensively implicated in 
many types of cancer. Specifically, it is a biomarker in breast cancer sera and proximal fluid [20,21] as 
well as in colon cancer [22]. Its presence in non-small cell lung carcinoma patients predicts poor 
survival and metastasis [23]. LOXL2 regulates cell polarity in breast carcinoma and is required for 
metastasis [24]. LOXL2 has been implicated in breast carcinoma [25] and its overexpression is 
associated with poor clinical outcome [26] and metastasis [27] for breast adenocarcinomas. 
Table 1. Mass spectrometry reveals novel binders of eHsp90. 
Peptide Score Peptide (*Hits) 
Heat Shock Protein 90 kDa alpha (cytosolic), class A member 1 isoform 2 288.34 112 (108 4 0 0 0) 
Galectin-3 Binding Protein 210.3 135 (135 0 0 0 0) 
Lysyl Oxidase-like 2 precursor 70.26 10 (10 0 0 0) 
Heat Shock Protein-1 beta 68.23 15 (10 5 0 0 0) 
Lysyl Oxidase-like 4 precursor 48.19 6 (4 2 0 0 0) 
Plasminogen Activator, tissue type isoform 1 preprotein 40.26 5 (5 0 0 0 0) 
Granulin precursor 40.23 5 (5 0 0 0 0) 
MAM domain containing 2 40.22 5 (5 0 0 0 0) 
Galactosylceramidase isoform a precurso 30.26 3 (3 0 0 0 0) 
Albumin precursor 30.23 4 (4 0 0 0 0) 
* indicates the number of peptides in each sample following trypsin digestion. 
We confirmed that LOXL2 binds eHsp90 by immunoblot analysis of immunoprecipitates both 
using anti-Hsp90 alpha followed by immunoblot with anti-LOXL2 as well as using anti-LOXL2 for 
coimmunoprecipitation followed by immunoblotting using anti-Hsp90 alpha (Figure 1). In contrast,  
we were unable to detect G3BP by this approach (data not shown). These findings suggest that LOXL2 
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(precursor) associates with Hsp90 alpha in conditioned media while G3BP precursor may be part  
of a complex with aggregates of extracellular matrix that nonspecifically precipitate when 
immunoprecipitating eHsp90. This may be due to G3BP’s ability to bind to the extracellular matrix 
and integrins or its binding to Galectin-3 [28,29]. 
Figure 1. eHsp90 binds to LOXL2 in conditioned media of breast cancer cells. 
Immunoprecipitation of hsp90 or LOXL2 from the conditioned media of MDA-MB231 
cells. Immunoprecipitation antibody (IP Ab) is indicated along the top row while the 
antibody used to probe the Western blot (IB) is indicated along the right side of the figure. 
 
Interestingly, Hsp90 beta was identified as a binder of Hsp90 alpha in MDA-MB231 conditioned 
media. Our initial studies using HT-1080 fibrosarcoma cells showed that only the alpha isoform was 
located on the HT1080 cell surface by immunohistochemistry [2]. This was an argument that eHsp90 
was not due to leakage of intracellular content but was specific. Since then however, several papers 
have shown alpha, beta or both isoforms of Hsp90 in the extsracellular environment [11,14,30]. For 
example, in MDA-MB453 cells have both isoforms in their conditioned media [14]. Our findings 
suggest that for MDA-MB231 cells that both isoforms are also present and we speculate that the 
isoform specificity may be cell-type dependent. 
2.2. Inhibiting eHsp90 Using STA-12-7191: An Impermeant Derivative of Ganetespib 
The singular targeting of eHsp90 is likely to inhibit many of its clients whose activities promote 
invasion leading to a more marked effect on metastasis compared to inhibition of any one of these 
proteins alone. Studies using mouse models of metastasis have indicated that inhibition of eHsp90 
using DMAG N-oxide or an inhibiting monoclonal antibody 4c5 reduced metastases [14,31]. Despite 
this promise, there are issues that limit the use of these inhibitors for drug development. DMAG  
N-oxide generates a metabolic product that can cause retinal damage while 4c5 is a large protein that 
may have concerns with tumor penetrance [32]. Recently, a tethered (and thus impermeant) Hsp90 
inhibitor (HS-27) has been reported [33] but it has not yet been tested clinically. Data presented herein 
introduce a novel impermeant small molecule Hsp90 inhibitor STA-12-7191 derived from the drug 
ganetespib, which has been tested in clinical trials [17]. Permeability assays show that STA-12-7191 has a 
ranked permeability of 0.02 × 10
−8
 cm/s (Table 2). In contrast, ganetespib has a permeability ranking of  
3.6 × 10
−6
 cm/s. Permeable compounds must have a ranking in the order of 10
−6
 cm/s. Thus, STA-12-7191 
is not only cell impermeant but also markedly less permeable than ganetespib. 
  
IP Ab: HSP90 LOXL2 No Ab
IB: HSP90
   90kDa
IB: LOXL2
  87 kDa
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Table 2. Permeability data for Hsp90 inhibitors indicates that STA-12-7191 is membrane impermeant. 
Compound 
Permeability 
(cm/s) (10E−06 cm/s) 
STA-12-7191 2.10E−08 0.021 
Ganetespib 3.6E−06 3.6 
Caffeine (+) 1.17E−05 11.7 
Furosemide (−) 1.47E−08 0.0147 
2.3. STA-12-7191 Is Markedly Less Toxic than Ganetespib 
STA-12-7191 is a biotinylated analog of ganetespib (Figure 2). Ganetespib binds to the ATP 
binding site of Hsp90 alpha with a Kd of 110 nM [34] and we measured this binding for STA-7191 
using an assay for labeled geldanamycin competition and measured an IC50 of 62 nM showing that  
it still binds tightly to the ATP binding site comparable to ganetespib itself. We postulate that  
STA-12-7191 does not readily penetrate the cell membrane due to the polar biotin moiety. This is 
shown by the 100-fold difference in the IC50 for its inhibition HER2 degradation, an intracellular 
function of Hsp90. STA-12-7191 had an EC50 for HER2 degradation of 2.7 µM in BT-474 breast 
cancer cells compared to an EC50 of 29 nM for ganetespib (Table 3). 
Figure 2. Structure of HSP90 inhibitors. The chemical structures for ganetespib and for 
STA-12-7191, a biotinylated derivative of ganetespib. 
 
Table 3. EC50 for Geldanomycin competition and HER2 degradation for ganetespib and STA-12-7191. 
 
Geldanamycin binding EC50 Her2 degradation EC50 
Ganetespib 110 nM 29 nM 
STA-12-7191 62 nM 2557 nM 
We first tested the effects of STA-12-7191 on cell viability on both cancer and non-cancer cells 
(Figure 3). Interestingly, the LD50 values varied markedly depending on the cell line tested. HEK293T 
GanetespibSTA-12-7191
Cancers 2014, 6 1036 
 
 
and A172 cells were more sensitive to both drugs than were MDA-MB231 cells. STA-12-7191 has a 
6-fold higher LD50 compared with ganetespib in HEK293T cells (54 nM vs. 306 nM), as we expect due 
to its reduced ability to cross the membrane. This is consistent with the difference between EC50 for 
geldanamycin binding and HER2 degradation for these two drugs shown in Table 3. This supports the 
notion that inhibiting eHsp90 is not toxic to normal cells and as a drug candidate might be tolerated at 
higher concentrations than ganetespib. We also observed a difference for LD50 between ganetespib  
and STA-12-7191 for A172 Glioblastoma cells though not as large as seen for HEK293T cells  
(157 nM vs. 387 nM). The LD50 for STA-12-7191 for HEK293T and A172 cells are similar but the  
LD50 for ganetespib is three fold higher perhaps due to drug resistance mechanisms. Interestingly  
for MDA-MB231 breast cancer cells while we again noticed a similar difference in LD50 for the  
two drugs this cell type is markedly more resistant to both drugs with LD50 values in µM range  
(2.54 µM vs. 9.34 µM). This is likely due to the high drug resistance inherent in these cells due to high 
expression of the multi-drug resistance pump, PGP-1 [35]. 
Figure 3. STA-12-7191 is markedly less toxic than ganetespib. CellTiterGlo was used to 
assess viability of HEK293T, MDA-MB231 and A172 cells after treatment with varying 
concentrations of either ganetespib (black) or STA-12-7191 for 5 days. Data are  
means ± SEM and representative of two independent experiments. LD50 values were 
determined using the drc package in R statistical software. 
 
As STA12-7191 is thought to be impermeant, the question is why it is toxic at all? Barrott et al. [6], 
have recently shown that tethered Hsp90 inhibitors can enter cells through an endocytic process 
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mediated by eHsp90. We speculate that STA-12-7191 also enters the cell via this process (or perhaps 
passive or active transport) albeit slowly relative to ganetespib leading to cell toxicity. This is consistent 
with the fact that STA-12-7191 inhibits HER2 degradation with a much higher IC50 than ganetespib. 
2.4. Testing STA-12-7191 to Inhibit eHsp90-Mediated Cell Migration 
We tested and compared ganetespib and STA-12-7191 to control for their efficacy in reducing 
cancer cell motility as assayed using wound healing assays. We test this using two cancer cell lines, 
MDA-MB231 breast cancer cells and A172 GBM cells. These cell lines were selected as highly invasive 
cancer cell lines based on cancers that have been shown to highly express eHsp90 [10] and that 
treatment with eHsp90 specific inhibitors (DMAG-oxide and 4c5) resulted in modest benefit in 
reducing metastasis. Lastly, we had previously used these cell lines to show eHsp90’s role in cell 
migration in culture [10]. We chose concentrations of 10 nM and 100 nM concentrations that bracket 
the IC50 for STA-12-7191 inhibition of geldanamycin binding (62 nM) but still markedly below the 
IC50 for HER2 degradation (620 nM) to minimize potential effects on intracellular Hsp90 functions by 
STA-12-7191. For MDA-MB231 cells, treatment with 10 nM ganetespib and STA-12-7191 blocked 
wound healing by 20% (Figure 4A,B). We also treated cells with 100 nM ganetespib which is below 
its LD50 for all cells tested, however the cells appeared to round up and became non-motile (data not 
shown). Therefore, we could not conclude if cell migration was inhibited due to this behavior or an 
effect on their viability. In contrast treatment of MDA-MB231 cells with 10 nM STA-12-7191 resulted 
in 30% inhibition of wound closure (p = 0.01 and treatment with 100 nM STA-12-7191 did not affect 
cell morphology and resulted in close to 60% inhibition of cell migration. This result was also seen 
using A172 GBM cells though no increased inhibition was seen at 100 nM STA-12-7191 (Figure 4C,D). 
These findings show that STA-7191 can inhibit cancer cell migration and can be used at higher 
concentrations that cannot be used for ganetespib. The fact that ganetespib was no better at inhibiting 
cell migration at 10 nM than STA-12-7191 suggests that the major role of Hsp90 on cell migration in 
this assay is based on its extracellular activity. The viability and wound healing data make a key point 
that at concentrations of STA-12-7191 that cells can tolerate it has a greater effect on migration  
while we can go up in STA-12-7191 beyond the tolerable dose for ganetespib and cause an even 
greater loss of cell migration. Interestingly, even 10 nM exceeds the Kd for ganetespib binding to the 
Hsp90-ATPase site suggesting perhaps a different mechanism beyond the ATPase binding pocket 
inhibition. It is also curious why an inhibitor that acts at this site should inhibit migration as we 
showed that ATP hydrolysis was not required for MMP2 activation by eHsp90 [36]. In fact, a  
non-hydrolysable form of ATP (gamma S) actually caused increased MMP2 activation. We speculate 
that while ATPase activity is not needed for eHsp90 activation of its clients, perhaps ATP binding 
facilitates conformation that enhances its action on its extracellular partners. 
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Figure 4. Inhibition of extracellular hsp90 reduces migration of breast cancer and brain 
tumor cell lines. (A) Representative images of MDA-MB231 breast cancer cells at 0 h  
(top panel) or 16 h (bottom panel) post wounding. Cells were treated with DMSO, 
Ganetespib (G), or STA-1791 (STA). Dotted lines outline the width of the wound 
unoccupied by cells; (B) Quantification of wound healing assay using MDA-MB231 cells. 
Data are represented as the percent closure relative to untreated cells (un). p value indicates 
significance compared to DMSO treated cells (two tailed t test). Data are means ± SEM;  
n = 4 experiments; (C) Representative images of A172 glioma cells at 0 h (top panel) or 16 h 
(bottom panel) post wounding. Cells were treated with DMSO, Ganetespib (G), or STA-1791 
(STA). Dotted lines outline the width of the wound sunoccupied by cells; (D) Quantification 
of wound healing assay using A172 cells. Data are represented as the percent closure at 16 h 
relative to 0 h for each treatment. p value indicates significance compared to DMSO treated 
cells (two tailed t test). Data are means ± SEM; n = 3 experiments. 
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Figure 4. Cont. 
 
2.5. LOXL2 Can Rescue of STA-12-7191 Inhibition of Cell Migration 
We addressed whether LOXL2, the novel eHsp90 binder that we found, has a role in eHsp90-mediated 
cell migration using the wound healing assay. The decrease of wound closure caused by 100 nM  
STA-12-7191 can be rescued by adding LOXL2 protein though not entirely (Figure 5). This is not 
surprising as there are many eHsp90 clients that act in cell migration including MMP2, MMP9, and 
TPA among others. We similarly tested G3BP for its role in wound healing and saw no significant 
effect of adding purified G3BP regardless of STA-12-7191 (data not shown). 
Figure 5. Role of eHsp90 on breast cancer cell motility is dependent upon. LOXL2. 
Quantification of wound healing assay using MDA-MB231 cells. Data are represented as 
the percent closure relative to vehicle treated cells (DMSO). Cells were treated with DMSO, 
50 ng recombinant human LOXL2 protein (LOXL2), 100 nM STA-12-7191 (STA), or the 
combination of both recombinant human LOXL2 protein with 100nM STA-12-7191.  
p values calculated using two tailed t test. Data are means ± SEM; n = 3 experiments. 
 
3. Experimental 
3.1. Cell Culture 
HEK293T, A172, COS7, and MDA-MB231 cells were obtained from ATCC and maintained in 
DMEM supplemented with 10% FBS, 1% NEAA and 1% P/S. SUM159 cells were a kind gift from 
Dr. Charlotte Kuperwasser (Tufts Univsersity School of Medicine, Boston, MA, USA) and were 
maintained in F-12 media supplemented with 5% FBS, 5 μg/mL insulin, 0.5 μg/mL hydrocortisone and 
1% P/S. All cells were grown in a 37 °C incubator with 5% CO2. 
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3.2. Immunoprecipitation/Mass Spectrometry 
Immunoprecipitation and mass spectrometry were performed as described in [10]. 4 × 10
6
 MDA-
MB231 breast cancer cells were plated in a 150 mm tissue culture dish and allowed to settle for 24 h. 
Cells were then re-fed with serum free media and incubated for 48 h at 37 °C. Conditioned media was 
concentrated by centrifugation (Millipore, Billerica, MA, USA) and a protein assay was performed 
(BioRad, Hercules, CA, USA). 1 mg of protein was pre-cleared with protein A beads after which 1 μg 
of hsp90α antibody (Assay Designs, Farmingdale, NY, USA) was added to the samples. Samples were 
washed with RIPA B buffer (50 mM Tris, 150 mM NaCl, 0.5% NP40, 0.25% DOC) boiled, subjected 
to SDS PAGE, stained with Coomassie Blue and removed from the gel for mass spectrometry analysis. 
The excised gel bands were analyzed by mass spectrometry as previously described [37]. 
Coimmunoprecipitation was performed as described above using 2.5 μg of LOXL2 Ab (R&D Systems, 
Minneapolis, MN, USA) was added to the samples. Samples were washed with RIPA B buffer, boiled 
and subjected to SDS-PAGE for western blotting. Blots were probed with mouse anti-HSP90alpha 
(Enzo Life Sciences, Farmingdale, NY, USA) and rabbit anti-LGALS3BP (Thermo Scientific, 
Tewkbury, MA, USA) primary and goat anti-rabbit and anti-mouse HRP-conjugated (GeneTex, Irvine, 
CA, USA and Enzo Life Sciences) secondary antibodies for blotting. 
3.3. Hsp90 Binding and HER2 Degradation Assays 
STA-12-7191 binding to Hsp90 alpha was determined using an Hsp90α assay kit from BPS 
Bioscience San Diego, CA, USA, Cat #50294) containing Hsp90alpha recombinant enzyme, FITC-labeled 
geldanamycin, assay buffer and a low binding 384-well plate. Binding was assessed using fluorescence 
polarization using a PHERAstar fluorescence plate reader (BMG Labtech, Ortenberg, Germany). 
HER2 degradation was assessed in BT474 breast cancer cells (ATCC# HTB-20) using Anti-HER2/neu 
FITC (BD Biosciences, San Jose, CA, USA) and assessing fluorescence as in the Hsp90 binding assay. 
3.4. Drug Toxicity and Viability Assays 
For each cell line tested, 7 × 10
3
 cells were plated into the central 60 wells of a 96-well tissue 
culture plate, and allowed to adhere for 24 h. Culture media was then replaced with media containing 
the drug, either ganetespib or STA-12-7191, with each concentration repeated in triplicate wells. Cells 
were maintained in drug-containing media for five days, with a media change on day three. Cell 
viability was then determined using the CellTiter-Glo assay kit (Promega, Madison, WI, USA). 
Luminescence values were normalized to vehicle control-treated cells. LD50 values were calculated 
and dose-response curves generated using the R statistical software package (R Core Team, 2013) 
using the drc library [38]. 
3.5. Wound Healing Assays 
1.5 × 10
5
 MDA-MB231 breast cancer cells or 0.7 × 10
5
 A172 glioma cells were plated in an eight 
well chamber slide. Cells were allowed to adhere for 24 h and then wounded by scratching a sterile 
yellow pipette tip length-wise along the chamber. The cells were washed once with 1× PBS and 
growth media was placed in each well with DMSO (vehicle control), 10 nM ganetespib, or 10 nM 
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STA-12-7191, or 100 nM STA-12-7191. Images were taken immediately after wounding (0 h) and 16 h 
after wounding. Wound width was calculated using Spot software. 
3.6. Membrane Permeability Assays 
Permeability for STA-12-7191 was conducted using Parallel Artificial Membrane Permeability 
Assay (BD Biosciences). In this assay the compounds were dissolved n DMSO, diluted with PBS and 
added to donor wells. The acceptor wells contained PBS only. Samples were incubated for 5 h at room 
temperature and samples were taken from both the acceptor and donor wells for analysis by LC/MS-MS. 
Caffeine was used as the positive control and furosemide was used as the negative control. 
4. Conclusions 
These studies introduce two new binders of eHsp90 in MDA-MB231 conditioned media: LOXL2 
and G3BP and are consistent with LOXL2 but not G3BP as a potential client of eHsp90. They also test 
for the first time STA-12-7191 an impermeant inhibitor of Hsp90 derived from ganetespib and show 
this compound is not only markedly less cytotoxic than ganetespib but it can also inhibit cancer cell 
migration in a wound healing assay. 
While the mass spectrometry analysis suggests that LOXL2 and G3BP associate with eHsp90 in 
conditioned media by mass spectrometry however, we only have evidence by immunoblot analysis for 
LOXL2 binding to eHsp90. Furthermore, addition of LOXL2 protein to the wound healing assay 
increases wound closure thereby compensating for STA-12-7191 inhibition of wound closure. Thus 
our findings support a role for LOXL2 (but not G3BP) as a potential client for eHsp90 and its 
established role in cancer makes it a potentially important one. To establish that LOXL2 is a bona fide 
eHsp90 client, it remains to be determined the mechanism by which these proteins are activated and 
their relevant substrates for invasion. While the mechanism of how LOXL2 acts in eHsp90 stimulated 
cancer cell migration is not clear but it has many functions that could promote cell migration. The lysyl 
oxidase activity of LOXL2 can crosslink ECM and inhibiting LOXL2 can markedly decrease 
crosslinked collagen in the stroma [39]. It is a substrate for MMP2 and MMP9 both of which are 
activated by eHsp90 [2,9]. An additional factor in LOXL2’s increase of cell motility and invasion is its 
ability to increase Focal Adhesion Kinase (FAK) phosphorylation leading to increases in focal 
adhesion dynamics [24,40]. LOXL2 also binds and regulate Snail during transcriptional regulation 
(intracellular roles) affecting EMT [26] but our IP/MS analyses were conducted on extracellular 
proteins and we will restrict the studies in this application to LOXL2’s extracellular roles. Future 
studies will be necessary to determine the mechanism of how LOXL2 is enhancing cellular migration 
as well as to determine if the mechanism is solely dependent on the extracellular activity of Hsp90. 
Hsp90 is an established cancer target with over twenty ongoing clinical trials testing the benefit  
of Hsp90 inhibitors in cancer treatment. For example, early results are promising from Synta 
Pharmaceutical’s phase 2 study of ganetespib in combination with docetaxel for advanced stage lung 
adenocarcinoma and this has led to a current phase-3 clinical trial [17]. Hsp90 has many intracellular 
functions and there may be toxicities associated with inhibiting all Hsp90 functions as suggested by the 
10-fold lower LD50 for ganetespib compared to STA-12-7191. While well tolerated, dosing is limited 
due to intracellular Hsp90 inhibition of normal cells. If a non-cytotoxic extracellular small molecule 
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inhibitor could be employed, this might serve as a compound to inhibit cancer cell migration to reduce 
cancer spread in vivo. This study investigates STA-12-7191 as an alternative candidate impermeant 
Hsp90 inhibitor that may have advantages over DMAG N-oxide and 4c5, which have been explored in 
metastasis models in mice. STA-12-7191 has advantages as a small molecule and is likely to be better 
tolerated in vivo than ganetespib. As STA-12-7191 does not readily penetrate the cell membrane, it is 
likely to be even less cytotoxic although this needs to be demonstrated in a pharmacotoxicity study. 
Such an impermeant eHsp90 inhibitor would avoid cytotoxicities associated with total Hsp90 
inhibition and may permit higher dosing with diminished side effects [6]. 
While previous studies suggest that inhibiting eHsp90 has benefit in reducing metastasis in  
two mouse models for melanoma [31] and breast cancer [14] their use for clinical applications may be 
limited. DMAG N-oxide (derived from 17AAG) is degraded in serum to DMAG, which has retinal 
toxicity issues [32]. MC5 is an anti-Hsp90 monoclonal antibody has promise but is expensive to 
prepare in amounts required for clinical trials and has not yet been examined for toxicity. Secondly, 
these studies used tail vein injection of human cancer cell lines, which really only assesses the later 
stages of metastasis (survival in circulation, implantation and homing) and also have an additional 
complication of using human cells homing to mouse organs. Thus far, the in vitro data from this study 
and others on eHsp90 implicate its role is in migration and invasion, the first steps of metastasis. How 
eHsp90 acts on homing and other later events in metastasis is not clear therefore in vivo models that 
directly test eHsp90’s role in invasion are required. 
The data presented herein introduce STA-12-7191 as an alternative to ganetespib. Future studies 
will be valuable in understanding the mechanism by which STA-12-7191 inhibits cellular migration, 
and if in fact, that mechanism differs from ganetespib migration inhibition. It will be imperative to 
examine STA-12-7191 in metastasis models that interrogate invasion as an early step in metastasis. 
While this study was focused on cells derived from breast cancer and glioblastoma, eHsp90 has also 
been found for other cancer cells including prostate and melanoma so it is possible that impermeant 
Hsp90 inhibitors may also have application to reduce invasion for these cancers. 
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